These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 26058416)
21. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Calleja EM; Warrell RP Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887 [TBL] [Abstract][Full Text] [Related]
22. Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia. Hasan SK; Lo-Coco F Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S139-43. PubMed ID: 21115433 [TBL] [Abstract][Full Text] [Related]
23. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431 [TBL] [Abstract][Full Text] [Related]
24. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687 [TBL] [Abstract][Full Text] [Related]
25. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433 [TBL] [Abstract][Full Text] [Related]
26. Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities. Rérolle D; Wu HC; de Thé H Cold Spring Harb Perspect Med; 2024 Sep; 14(9):. PubMed ID: 38503502 [TBL] [Abstract][Full Text] [Related]
27. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Zhu J; Lallemand-Breitenbach V; de Thé H Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854 [TBL] [Abstract][Full Text] [Related]
28. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner. Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653 [TBL] [Abstract][Full Text] [Related]
29. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108 [TBL] [Abstract][Full Text] [Related]
30. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606 [TBL] [Abstract][Full Text] [Related]
31. Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report. He Y; Li X; Wang D; Zhang E; Hu Y; Wang W; Huang R; Xiao R J Int Med Res; 2014 Dec; 42(6):1363-73. PubMed ID: 25223426 [TBL] [Abstract][Full Text] [Related]
32. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. Nichol JN; Garnier N; Miller WH Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014 [TBL] [Abstract][Full Text] [Related]
33. The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. Rice KL; de Thé H J Intern Med; 2014 Jul; 276(1):61-70. PubMed ID: 24635409 [TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
36. Autophagic degradation of an oncoprotein. Bøe SO; Simonsen A Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820 [TBL] [Abstract][Full Text] [Related]
37. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Vitoux D; Nasr R; de The H Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032 [TBL] [Abstract][Full Text] [Related]
38. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639 [TBL] [Abstract][Full Text] [Related]
39. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Valenzuela M; Glorieux C; Stockis J; Sid B; Sandoval JM; Felipe KB; Kviecinski MR; Verrax J; Buc Calderon P Br J Cancer; 2014 Aug; 111(5):874-82. PubMed ID: 25003661 [TBL] [Abstract][Full Text] [Related]
40. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia. Wang X; Lin Q; Lv F; Liu N; Xu Y; Liu M; Chen Y; Yi Z Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]